Burkitt Lymphoma International Prognostic Index

Area of Science:

• Hematology
• Oncology
• Clinical Prognostics

Background:

• Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma with unique biology.
• A standardized prognostic model for BL is currently lacking.
• Accurate risk stratification is crucial for treatment planning and clinical trial design.

Purpose of the Study:

• To develop and validate a novel prognostic index specifically for adult Burkitt lymphoma.
• To improve risk stratification for BL patients.
• To facilitate interpretation of clinical trials and guide development of new treatments.

Main Methods:

• The BL International Prognostic Index (BL-IPI) was derived from a US-based real-world dataset of adult BL patients treated with immunochemotherapy (2009-2018).
• Candidate variables associated with progression-free survival (PFS) were identified.
• The BL-IPI was validated using an external dataset from Europe, Canada, and Australia (2004-2019).

Main Results:

• The BL-IPI incorporates age ≥ 40, performance status ≥ 2, elevated lactate dehydrogenase, and central nervous system (CNS) involvement.
• In the derivation cohort (n=633), the BL-IPI identified low (18%), intermediate (36%), and high (46%) risk groups with distinct 3-year PFS (92%, 72%, 53%) and overall survival (96%, 76%, 59%) rates.
• Validation in 457 patients confirmed the index's ability to discriminate outcomes across different patient subgroups and geographic regions.

Conclusions:

• The BL-IPI offers robust survival discrimination for adult BL patients.
• It is suitable for prognostication and stratification in clinical trials.
• High-risk patients identified by BL-IPI have poor outcomes with standard therapy and warrant consideration for innovative treatment approaches.